Anemia Drugs Market is Expected to Grow at a CAGR of 8.9% from 2022 to 2030

Pune, India, April 10, 2022 /MRFR Press Release/- Market research future published a half-cooked research report on global Anemia Drugs market. The global Anemia Drugs market is expected to grow at a CAGR of 8.9% during the period 2022 to 2030.

Market Highlights

Anemia is one of the most common disorder related to blood and affects a whooping one quarter of the world population. It is characterized by tiredness, shortness of breath, lack of exercise capacity, weakness etc. The reason for the above symptoms are the lowered capacity of blood to carry oxygen due to imbalance in the level of red blood cells. The disease has a propensity towards women especially pregnant and lactating and geriatrics.

The anemia drugs market is projected to grow at 8.9% CAGR, to reach USD 15,983.5 Million in the forecast period 2022-2030.

The global anemia market is growing at a good rate and the market is expected to make a transition in favor of developing regions. The driving factors are growth of geriatric population, increasing awareness, increasing focus of social healthcare on women health and particularly anemia, rise in accidents and cancer, rise in other risk factors such as diabetes, modern lifestyle induced stress, poor nutritional habits, rise in lactating and pregnant women in developing regions, intestinal infections etc.

The market opportunity is huge and the market is quite fragmented with a number of players. There is a huge unmet market especially in developing regions. In some nations the market can also be segmented into contract and private, with the contract market led by government contracts for anemic drugs for social health programs.

The drugs such as parenteral and oral iron supplements have a poor absorption and side effects associated with them. The market is devoid of a good efficacious drug and development pipeline represents a huge opportunity. Other restraints on the market is growing incomes of developing regions which will result in loss of patients affected by anemia due to nutritional factors.

Browse In-depth Market Details [Table of Content, List of Figures, List of Tables] of  Anemia Drugs Market Research Report

Global Anemia Drugs Market:

The Global anemia drugs market has been evaluated as a growing market and it is expected that the market will touch high growth figures in future. The global anemia drugs market is expected to grow with CAGR of ~8.4% during the forecast period. The rise will be led by the developing regions and market development will represent a good strategy. Market penetration is comparatively easy and the market is also devoid of a very efficacious drug. Thus research and development collaboration between companies will be a smart strategy. The rising healthcare funding in developing regions also provide a good opportunity for further market development. Biologics development pipeline represent another potential alternative for developing anemia drugs.

Key Players:

The major participants of this market are: Amgen Inc., GlaxoSmithKline plc, Bluebird bio, Biocon, GlycoMimetics Inc., Regen biopharma Inc., Bayer AG, Acceleron Pharma, Eli Lilly and company and others.

Regional Analysis:

Depending on geographic region, Anemia Drugs market is segmented into four key regions: America, Europe, Asia Pacific, and Middle East & Africa. Globally, America is the largest market for anemia drugs closely followed by Europe. Asia pacific region is however the fastest growing region in anemia drugs market due to unmet medical needs, changing socio-economic conditions, greater awareness towards women health etc. 

Market Segmentation:

Global anemia drugs market has been segmented on the basis of anemia type which comprises iron deficiency anemia, sickle cell anemia, aplastic anemia, hemolytic anemia pernicious anemia and others. On the basis of route of administration; market is segmented into oral and injectable. On the basis of product type; market is segmented into biologics and non-biologics. On the basis of end users; market is segmented into hospitals, self-administered and others.